=Viking Therapeutics (VKTX) : liver drug succeeds in mid-stage study

Viking Therapeutics announces 'positive' top-line results from a 12-week Phase 2 study of VK2809 
The study successfully achieved its primary endpoint, with patients receiving VK2809 demonstrating statistically significant reductions in LDL-C compared with placebo. In addition, the trial's secondary endpoint was achieved, with VK2809-treated patients experiencing statistically significant reductions in liver fat content compared with placebo. An abstract describing the results has been submitted for consideration for presentation at The Liver Meeting 2018, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), scheduled for November 9-13, 2018 in San Francisco, CA. No serious adverse events (SAEs) were reported among patients receiving VK2809 or placebo.